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Randomized Comparison of Flow Reversal vs Distal Filter for Cerebral Protection
During Carotid Artery Stenting in Patients With Stable Carotid Disease
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Background: previous studies revealed high incidence (up to 80%) of new asymp-
tomatic cerebral lesion after CAS, with conﬂicting results comparing proximal pro-
tection with ﬁlter. Heterogeneity in patient selection, CAS techniques and operators’
experience could have biased previous results. We sought to establish if proximal
protection with ﬂow reversal, performed by experienced operators in a high volume
center, may be more effective than ﬁlters in preventing cerebral embolization during
CAS in patients with stable carotid disease.
Methods: patients undergoing CAS with cerebral embolic protection for internal carotid
artery stenosis were randomly assigned to ﬂow reversal (FR) or ﬁlter protection (FP).
The primary endpoint was the incidence of new cerebral ischemic lesions assessed by
diffusion-weighted magnetic resonance imaging (MRI). Secondary endpoints were: the
number and diameter of new ischemic lesions; the number of microembolic signals
(MES) assessed by bilateral transcranial Doppler monitoring during the all phases of the
procedure. Major cardiovascular and cerebral events (MACCE) at 30 days were
recorded. Expected rate of new cerebral lesion was 50% in FP, 17% in FR (as reported
in previous studies); with alfa 5% and 1-beta 80%, sample size was 60 patients.
Results: 60 consecutive patients (mean age 72+6.8)were randomized. Comparedwith FP
(n¼30), FR (n¼30) did not reduce the incidence, the number and the diameter of new
cerebral ischemic lesions (table). Lesions in the contralateral hemisphere were found in
3.3% and 0% of patients. Overall MES were not signiﬁcantly reduced by FR compared to
FP (table). The 30 day MACCE rate was 3.3% and 3.3% for FP versus FR (p NS).ﬁlter
(n¼30)
proximal
protection
(n¼30) p
patients with at least 1 new lesion 12 (16.6%) 3 (10%) 0.7
number of new lesions (mean + SEM) 0.4 + 0.26 0.16 + 0.1 0.41
diameter (mean + SEM) 4.83 + 0.5 6.6 + 1.6 0.18
MES (median (interquartile range)) 125 (91-161) 103 (87-185) 0.6Conclusions: in this randomized trial of patients with stable severe carotid disease
undergoing CAS, incidence of new ischemic lesions was very low in both groups. FR
protection did not signiﬁcantly reduce cerebral embolization.1164
PROCEDURES TOTAL
> 80 Y.
TOTAL
< 80 Y.
WITHOUT
EPD
WITH
EPD
WITHOUT
EPD
WITH
EPD
NBR 177 6 171 987 182 805
T.I.A. 3 (1,3%) 1 (17%) 2 (1,1%) 11 (1,1%) 3 (1,6%) 8 (1%)
MINOR STROKE 1 (0,6%) 1 (17%) 0 6 (0,6%) 3 (1,6%) 3 (0,4%)
MAJOR STROKE 0 0 0 3 (0,3%) 2 (1,1%) 1 (0,1%)
DEATH 0 0 0 5 (0,5%) 2 (1,1%) 3 (0,4%)
MI 0 0 0 1 (0.1%) 0 1 (0.1%)
DEATH /
STROKE / M.I.
1 (0,6%) 1 (17%) 0 15 (1,5%) 7 (3,8%) 8 (1,1%)
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Particulates from Hydrophilic Coated Guiding Sheaths Embolize to the Brain
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Background: Peripheral vascular interventions frequently employ guiding sheathswith
surface modiﬁcations (ie, hydrophilic coatings) raising the concern for embolization.
Methods: A self-expanding stent and delivery system (SDS) were deployed in the
iliac and/or carotid arteries of 23 Yucatan miniswine. Access was via the femoral or
carotid arteries. SDS were deployed through a Cook Flexor Ansel Guiding Sheath
with a hydrophilic coating (AQ hydrophilic coating). In one non-stented control
animal the guiding sheath was advanced but no SDS was deployed. Animals were
euthanized at 3, 30, 90 & 180 days after intervention and brains were removed for
histological analysis. In addition, coating material from the surface of a non-deployed
guiding sheath was obtained and examined microscopically.
Results: The Cook guiding sheath was associated with intravascular accumulation of
an amorphous, non-refractile, non-crystalline, and non-birefringent embolic foreign
material in sections of porcine brain which, on H&E staining, appeared lightly
basophilic and slightly stippled. Material was observed at all time points and in all
major regions of the brain, involving 52% of all test animals, and in the non-stented
control animal. The incidence of embolic material was higher (63%) with carotid
access than femoral access (20%). Evidence of adverse effects related to embolized
material was limited to a single incidence of focally extensive chronic infarction in one
brain. In vitro incubation of the Cook guiding sheath was associated with progressive
separation and sloughing of its hydrophilic coating. Microscopic assessment of the
sloughed hydrophilic coating was interpreted to be morphologically consistent with
the emboli observed in the brains of animals exposed to the Cook guiding sheath.
Conclusions: The hydrophilic coating of Cook Flexor Ansel Guiding Sheaths
sloughed and embolized to the brain during deployment in a porcine model, especially
following carotid access. Further monitoring and documentation of potential side-
effects of embolized material in clinical scenarios is warranted.B162 JACC Vol 64/11/SuppTCT-553
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Evaluation of ﬂow reversal during carotid artery stenting as the ﬁrst choice for
embolic protection - no contraindications!
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Background: To assess the use of proximal protection devices in consecutive patients
as the preferred means of cerebral embolic protection for primary stenting of carotid
stenosis.
Methods: This was a prospective single-center study to evaluate the technical and
clinical success of proximal protection devices as the ﬁrst choice for embolic protection
in symptomatic (50%) and asymptomatic (70%) carotid stenosis. Proximal protec-
tion devices were used for embolic protection in 124 consecutive patients. No patients
had been excluded for anatomical reasons. The Gore Flow Reversal Device (W.L.Gore,
Flagstaff, AZ) was used in 92 patients, the Mo.Ma Ultra device in 32 (Medtronic,
Minneapolis, MN) patients. We have used the Mo.Ma Ultra so that we were able to
establish a ﬂow reversal with this system, too. Follow-up duration was 30 days.
Results: Mean age was 71  8 years. Seventy-ﬁve percent of patients were male
(n¼93). Twenty-six of 124 (21%) treated stenoses were symptomatic. Technical success
was achieved in 122 of 124 cases (98%). Due to the anatomical conditions, in 2 patients,
ﬂow reversal could not be established. In both cases, additional distal ﬁlter devices were
used. Carotid stenting was successful in 124 lesions (100%). Ten patients (8.1%) had
classic contraindications to ﬂow reversal (3 high-grade ostial stenoses of the external
carotid artery, 7 contralateral occlusions of the internal carotid artery) in none of whom
any complications occurred. There were no procedural neurological events. Within 30
days of follow-up, one patient had an ischemic stroke on day 11.
Conclusions: Proximal protection using ﬂow reversal is a safe method as the ﬁrst
choice of embolic protection. It can be used with a high rate of technical success.
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CAROTID ANGIOPLASTY AND STENTING IN OCTOGENARIANS.
IS AS SAFE AS SURGERY. NEW DATA
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Background: Recent studies, registries (EXACT, CAPTURE.) randomized studies
(CREST) have shown that carotid angioplasty stenting (CAS) is at higher risk than
surgery (CEA) in elderly patients. The aim of this study was to evaluate if CAS
performed in octogenarians is as safe as surgery with better indications, choice of the
devices, experienced operators.
Methods: 1104 patients (male 794) mean age 70.8  9.7 years underwent 1164 CAS
for de novo lesions (n¼1022) restenoses (n¼57) post radiation (n¼15) inﬂammatory
arteritis (n¼12) post trauma aneurysms (n¼2). Indications for treatment: symptomatic
carotid stenosis > 70 % (63%) or asymptomatic stenosis > 80 %. Patients were
separated into 2 age groups: > 80 y (174 patients, 177 CAS) and < 80 y (930 patients,
987 CAS). 188 CAS performed without protection (N.P-) 6 in patients >80 y, 976
with protection (NP+) (occlusion balloon: 334, ﬁlters: 637, reversal ﬂow: 6) 171 in
patients >80y. Data analysis included neurological complications, death and
myocardial infarction (MI) rate at 30 days, anatomical particularities. Technical points
will be described depending on the age of the patient.
Results: -Technical success < 80 years: 985/987 >80 years: 176/177
-Technical success
< 80 years: 985/987
>80 years: 176/177
-30 day outcomesl B j September 13–17, 2014 j TCT Abstracts/Carotid Intervention
